See more : Asahi Diamond Industrial Co., Ltd. (6140.T) Income Statement Analysis – Financial Results
Complete financial analysis of Moringa Acquisition Corp (MACAU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Moringa Acquisition Corp, a leading company in the Shell Companies industry within the Financial Services sector.
- Softfront Holdings (2321.T) Income Statement Analysis – Financial Results
- The TJX Companies, Inc. (0LCE.L) Income Statement Analysis – Financial Results
- CONX Corp. (CONXU) Income Statement Analysis – Financial Results
- Dometic Group AB (publ) (DTCGF) Income Statement Analysis – Financial Results
- Nyrstar NV (0RH8.L) Income Statement Analysis – Financial Results
Moringa Acquisition Corp (MACAU)
About Moringa Acquisition Corp
Moringa Acquisition Corp does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses. It focuses on pursuing opportunities in technology-based businesses or industries in Israel. The company was incorporated in 2020 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.12M | 1.23M | 943.93K | 783.44K |
| Selling & Marketing | -1.12B | 0.00 | 0.00 | 195.08K |
| SG&A | 1.12M | 1.23M | 943.93K | 195.86K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.12M | 1.23M | 943.93K | 195.86K |
| Cost & Expenses | 1.12M | 1.23M | 943.93K | 195.86K |
| Interest Income | 0.00 | 1.69M | 6.37K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.12M | 1.23M | 943.93K | 783.44K |
| EBITDA | -1.12M | -1.36M | -1.13M | -195.86K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.12M | -3.31M | -1.13M | -195.86K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.39M | 1.82M | 188.72K | 0.00 |
| Income Before Tax | 263.07K | 584.03K | -755.22K | -195.86K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.12K | -1.95M | -188.72K | -783.44 |
| Net Income | 263.07K | 2.53M | -566.50K | -195.86K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.04 | 0.17 | -0.04 | -0.01 |
| EPS Diluted | 0.04 | 0.17 | -0.04 | -0.01 |
| Weighted Avg Shares Out | 6.13M | 15.06M | 14.86M | 14.86M |
| Weighted Avg Shares Out (Dil) | 6.13M | 15.06M | 14.86M | 14.86M |
Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded Via Business Combination with Moringa Acquisition Corp
MORINGA ACQUISITION CORP ANNOUNCES CONTRIBUTION TO TRUST ACCOUNT IN CONNECTION WITH PROPOSED EXTENSION
Source: https://incomestatements.info
Category: Stock Reports